MD3886820T2 - Formulări de capsule - Google Patents

Formulări de capsule

Info

Publication number
MD3886820T2
MD3886820T2 MDE20210972T MDE20210972T MD3886820T2 MD 3886820 T2 MD3886820 T2 MD 3886820T2 MD E20210972 T MDE20210972 T MD E20210972T MD E20210972 T MDE20210972 T MD E20210972T MD 3886820 T2 MD3886820 T2 MD 3886820T2
Authority
MD
Moldova
Prior art keywords
compound
solid solution
relates
capsule formulations
methods
Prior art date
Application number
MDE20210972T
Other languages
English (en)
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3886820(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MD3886820T2 publication Critical patent/MD3886820T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Prezenta invenţie se referă la formulări de capsule cu soluţie solidă de compus 1 şi metode de obţinere a acestora. De asemenea, prezenta invenţie se referă la metode de tratare a indivizilor, care suferă sau sunt susceptibili la o boală sau o tulburare, care implică activarea patologică a receptorilor c5a, prin administrarea unei cantităţi eficiente de una sau mai multe capsule cu soluţie solidă care conţine compusul 1. De asemenea, invenţia se referă la capsule cu doza unică, care conţin anumite cantităţi de compus 1, şi truse care cuprind o capsulă cu soluţie solidă cu conţinut de compus 1.
MDE20210972T 2018-11-30 2019-11-27 Formulări de capsule MD3886820T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
PCT/US2019/063547 WO2020112961A1 (en) 2018-11-30 2019-11-27 Capsule formulations

Publications (1)

Publication Number Publication Date
MD3886820T2 true MD3886820T2 (ro) 2023-07-31

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210972T MD3886820T2 (ro) 2018-11-30 2019-11-27 Formulări de capsule

Country Status (28)

Country Link
US (2) US20200170957A1 (ro)
EP (2) EP3886820B8 (ro)
JP (1) JP7342124B2 (ro)
KR (1) KR102586747B1 (ro)
CN (1) CN113164403A (ro)
AR (1) AR117219A1 (ro)
AU (1) AU2019389031B2 (ro)
BR (1) BR112021010285A2 (ro)
CA (1) CA3120999A1 (ro)
CL (1) CL2021001389A1 (ro)
CY (1) CY1126079T1 (ro)
DK (1) DK3886820T3 (ro)
ES (1) ES2943492T3 (ro)
FI (1) FI3886820T3 (ro)
HR (1) HRP20230551T1 (ro)
HU (1) HUE062551T2 (ro)
IL (1) IL283450B1 (ro)
LT (1) LT3886820T (ro)
MA (1) MA54318B1 (ro)
MD (1) MD3886820T2 (ro)
MX (1) MX2021006242A (ro)
PL (1) PL3886820T3 (ro)
PT (1) PT3886820T (ro)
RS (1) RS64250B1 (ro)
SG (1) SG11202105572UA (ro)
SI (1) SI3886820T1 (ro)
TW (1) TWI827745B (ro)
WO (1) WO2020112961A1 (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3886820T2 (ro) 2018-11-30 2023-07-31 Chemocentryx Inc Formulări de capsule
WO2023225533A1 (en) * 2022-05-19 2023-11-23 Dow Global Technologies Llc Use of peg-based interpolymer complexes for improved solubilization of bcs class ii drugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2010075257A1 (en) 2008-12-22 2010-07-01 Chemocentryx, Inc. C5ar antagonists
WO2011112558A2 (en) * 2010-03-10 2011-09-15 Abbott Laboratories Solid compositions
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
AU2015215000B2 (en) 2014-02-05 2017-10-19 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
ES2926828T3 (es) 2014-09-29 2022-10-28 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
TWI791423B (zh) 2016-01-14 2023-02-11 美商卡默森屈有限公司 C3腎絲球病變之治療方法
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2018184739A1 (en) 2017-04-03 2018-10-11 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
US20190144389A1 (en) 2017-10-30 2019-05-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
MD3886820T2 (ro) 2018-11-30 2023-07-31 Chemocentryx Inc Formulări de capsule

Also Published As

Publication number Publication date
TW202038952A (zh) 2020-11-01
EP3886820A4 (en) 2022-08-24
IL283450A (en) 2021-07-29
EP3886820B8 (en) 2023-05-17
EP4233850A2 (en) 2023-08-30
EP3886820B1 (en) 2023-04-12
IL283450B1 (en) 2024-02-01
LT3886820T (lt) 2023-06-12
KR20210098489A (ko) 2021-08-10
JP7342124B2 (ja) 2023-09-11
SG11202105572UA (en) 2021-06-29
BR112021010285A2 (pt) 2021-08-17
SI3886820T1 (sl) 2023-07-31
MA54318A (fr) 2021-10-06
US20200170957A1 (en) 2020-06-04
RS64250B1 (sr) 2023-06-30
EP3886820A1 (en) 2021-10-06
AU2019389031A1 (en) 2021-06-17
FI3886820T3 (fi) 2023-05-25
AR117219A1 (es) 2021-07-21
CN113164403A (zh) 2021-07-23
CY1126079T1 (el) 2023-11-15
US11951214B2 (en) 2024-04-09
HRP20230551T1 (hr) 2023-08-18
ES2943492T3 (es) 2023-06-13
CL2021001389A1 (es) 2021-12-24
WO2020112961A1 (en) 2020-06-04
PL3886820T3 (pl) 2023-08-14
JP2022510304A (ja) 2022-01-26
PT3886820T (pt) 2023-05-24
MA54318B1 (fr) 2023-08-31
CA3120999A1 (en) 2020-06-04
DK3886820T3 (da) 2023-05-15
MX2021006242A (es) 2021-09-10
TWI827745B (zh) 2024-01-01
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
KR102586747B1 (ko) 2023-10-06
AU2019389031B2 (en) 2023-06-15
US20220233453A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201290286A1 (ru) Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MD3886820T2 (ro) Formulări de capsule
CL2022000195A1 (es) Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MD3762368T2 (ro) Compuși diol aminopirazină ca inhibitori ai PI3K-Y
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
EA202190662A1 (ru) Фармацевтические комбинации для лечения опухоли, содержащие антитело к cd19 и естественные клетки-киллеры
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
EA202091307A1 (ru) Накожная система мониторинга состояния человека
PH12020551471A1 (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
CO2017010151A2 (es) Material de implante compuesto
MX2021001780A (es) Composiciones para el tratamiento de telas que comprenden capsulas de agente de beneficio.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201791525A2 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
EA202191063A1 (ru) Новая дозированная форма
EA202191469A1 (ru) Восстановление посредством антисмысловых олигонуклеотидов abca4 с аберрантным сплайсингом
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение